Skip to main content

Murat Osman Arcasoy

Professor of Medicine
Medicine, Hematology
Duke Box 3912, Durham, NC 27710
Hosp South Trent Drive, Box 3912 DUMC, Durham, NC 27710

Overview


Dr. Arcasoy's research interests include 1)The role of cytokines and cytokine receptors in hematopoietic commitment and lineage-specific differentiation 2) Mechanisms of tissue-specific expression of erythropoietin receptor (EPOR) gene and its role in lineage commitment and lineage-specific differentiation 3) Studies of the molecular basis of familial and congenital myeloproliferative disorders.4). Isolation of novel hematopoietic cytokine-responsive genes and study of their function and regulation 5). Characterization of novel non-hematopoietic functions of EPOR signaling

Dr. Arcasoy's laboratory has been studying the expression, regulation and function of the EPOR gene focusing on the function of naturally occurring mutations of the EPOR gene that result in primary familial and congenital polycythemia as well as the non-hematopoietic expression and functions of EPOR in vascular endothelium, macrophages, cardiac myocytes and cancer cells. We have also been studying global gene expression in erythroid cells from patients with polycythemia vera to better characterize the molecular signature of the disorder and develop new diagnostic tools.

Current Appointments & Affiliations


Professor of Medicine · 2016 - Present Medicine, Hematology, Medicine
Member of the Duke Cancer Institute · 2012 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published February 12, 2021
This Nurse Treated Cancer Patients for Years. Then Her Husband Became One.

View All News

Recent Publications


Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.

Journal Article Clin Adv Hematol Oncol · March 2024 The treatment landscape for BCR/ABL-negative myeloproliferative neoplasms (MPNs), driven by JAK2, CALR, and MPL mutations, has evolved significantly over the last decade. Recent regulatory approvals in polycythemia vera (PV) include the JAK inhibitor ruxol ... Link to item Cite

Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.

Journal Article Bone Marrow Transplant · February 2024 Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF) and is recommended for patients with higher risk disease. However, there is a risk of early mortality, and optimal timing is unknown. JAK inhibitor (JAK ... Full text Link to item Cite
View All Publications

Education, Training & Certifications


Aegean University, School of Medicine (Turkey) · 1987 M.D.